Activity Stream
@moatrx
• 3 weeks ago
Posted a new blog:
US HR+/HER2- BREAST CANCER Competitive Intelligence
US HR+/HER2- BREAST CANCER Competitive Intelligence
Ribociclib is the only CDK4/6 inhibitor with a significant survival edge: 63.9 versus 51.4 months, while palbociclib's OS gain never reached significance.
The...
